Clinical Trial

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-02
Trial Details
NCT Number NCT07565220
Lead Sponsor Sawa Ito, MD
Conditions Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS), Myeloproliferative Neoplasm (MPN)
Enrollment 48 participants
Start Date 2026-08-01
Primary Completion 2029-06-01 (estimated)
Study Completion 2030-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01